Page 50 - Alkermes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Integral Health Asset Management LLC purchased a new position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 179,000 shares of the company’s stock, valued at approximately $5,046,000. Other large investors have also modified their holdings of the company. Cibc World Markets Corp acquired […]

The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.

Biotech is still booming, if you pick the right biotech stocks.

With its stock down 9.6% over the past three months, it is easy to disregard Alkermes (NASDAQ:ALKS). But if you pay...

Eagle Asset Management Inc. increased its position in shares of Alkermes plc (NASDAQ:ALKS – Free Report) by 25.2% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 802,279 shares of the company’s stock after acquiring an additional 161,434 shares during the period. Eagle Asset Management […]